Epidemiology and transmission routes
Viral hepatitis C accounts for a significant share of pediatric hepatological pathology. According to statistics, it accounts for about 41% of all chronic hepatitis cases in children. Sources of infection in the population include patients with manifest (pronounced) and asymptomatic forms of the disease, as well as virus carriers.
In pediatric practice, the following main routes of infection are distinguished:
- Perinatal (vertical) route. Transmission of the pathogen from an infected mother to the child. This route is the most common in childhood.
- Parenteral route. Infection can occur in early childhood during various medical manipulations, as well as dental procedures. In adolescents, intravenous drug use becomes a major risk factor.
- Sexual route. Becomes relevant in older adolescence.
The insidious nature of viral hepatitis C lies in the fact that the acute phase of the infection in the vast majority of cases (more than 95%) proceeds completely covertly. As a result, the disease is characterized by an extremely high risk of chronicity: from 60 to 80% of acute forms progress to a chronic process. Mixed infections are also encountered in practice. The hepatitis C virus can combine with the hepatitis B virus (about 5%), hepatitis G (1%), and sometimes a triple infection is registered — HCV + HBV + HDV (about 1%).
Clinical presentation
The clinical symptoms of Hepatitis C chronica have much in common with the clinical picture of chronic hepatitis B, but the manifestations are usually significantly less pronounced. The disease can proceed latently (asymptomatically) for a long time without causing significant complaints about well-being in the child.
Among specific objective manifestations, a moderate increase in liver size (hepatomegaly) comes to the fore. During laboratory monitoring, such patients exhibit an intermittent cytolysis syndrome, which most often has a low degree of activity.
An important distinguishing feature of chronic hepatitis C is a high tendency to develop extrahepatic manifestations. Various systemic lesions occur in 45% of infected patients, which requires a careful, comprehensive examination of the child.
Specific diagnostics
The diagnosis is established comprehensively, taking into account clinical symptoms, laboratory, and instrumental data. At the same time, etiological verification, which is based on the detection of specific virus markers, is of decisive importance.
Basic diagnostics and differential diagnosis are based on serological screening (ELISA method). The following are determined in blood serum:
- Antibodies to the virus (anti-HCV IgM and IgG).
- Antibodies to non-structural viral proteins (anti-NS3 IgG, anti-NS4ab IgG, anti-NS5a IgG).
To confirm the diagnosis and assess the activity of the process, molecular genetic markers (PCR method) are used. Detection of viral RNA (HCV RNA) is of key clinical importance. This is the earliest marker of infection, which can be detected as early as 14–28 days after infection. The presence of HCV RNA reliably indicates active viral replication in the body.
Treatment approaches and prognosis
The choice of therapeutic tactics depends on the child's age and available regimens. Without treatment, chronic hepatitis C has an unfavorable prognosis: the disease naturally progresses to liver cirrhosis (LC), which ultimately requires organ transplantation. However, with effective therapy, the prognosis for life is assessed as favorable.
Pediatric practice (approved from 3 years of age): The drugs of choice are combination therapy regimens. Pegylated interferon alfa-2b combined with a nucleoside analogue (ribavirin) is considered the standard. The use of short-acting interferon alfa-2a is also possible, but its efficacy is proven to be lower.
Adult practice and prospects for children: In adult patients, modern interferon-free regimens based on direct-acting antivirals (DAAs) are widely used. These include combinations of sofosbuvir, ledipasvir, and daclatasvir (including together with ribavirin). The main advantages of such regimens are high clinical efficacy, safety, and the achievement of a sustained virological response. Active clinical trials are currently underway to introduce these regimens into pediatric practice.
To remember antibodies to non-structural proteins in ELISA: remember the numbers in order — 3, 4, 5 (NS3, NS4ab, NS5a).
Class and exam questions
Which hepatitis C marker appears first in the blood?
Viral RNA (HCV RNA), detected by PCR. This is the earliest marker of infection, which begins to be detected in blood serum as early as 14–28 days after infection.
From what age is antiviral therapy for hepatitis C permitted in children?
In pediatric practice, combination therapy regimens (pegylated interferon combined with ribavirin) are approved for use in children starting from 3 years of age.
Why does the infection so often transition into a chronic form?
The acute phase of viral hepatitis C in the vast majority of cases (>95%) is covert. Due to the lack of symptoms, the disease is rarely detected in time, and up to 80% of acute forms progress to chronic ones.
What is the advantage of direct-acting antivirals (DAAs)?
Interferon-free regimens based on DAAs are characterized by high efficacy, safety, and allow achieving a sustained virological response. Research is currently underway to introduce them into pediatrics.
What else to study on this topic
- Extrahepatic manifestations of chronic hepatitis C in childhood
- Features of the clinical picture and course of mixed infections (HCV + HBV + HDV)
- Interpretation of ELISA results: clinical significance of anti-NS3, anti-NS4ab, and anti-NS5a
- Direct-acting antivirals (DAAs): classification and mechanisms
- Mechanism of action of pegylated interferons and ribavirin
Master the entire topic in the Pediatrics course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Chronic hepatitis C in children" and 3,738 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 71 video lessons on the subject
Other topics in "Chapter 7. Digestive System Diseases"
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.